|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Baazim H, Antonio-Herrera L and Bergthaler
A: The interplay of immunology and cachexia in infection and
cancer. Nat Rev Immunol. 22:309–321. 2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Fearon K, Strasser F, Anker SD, Bosaeus I,
Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N,
Mantovani G, et al: Definition and classification of cancer
cachexia: An international consensus. Lancet Oncol. 12:489–495.
2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Fukahori M, Shibata M, Hamauchi S,
Kasamatsu E and Machii K: A retrospective cohort study to
investigate the incidence of cancer-related weight loss during
chemotherapy in gastric cancer patients. Support Care Cancer.
29:341–348. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Namikawa T, Marui A, Yokota K, Fujieda Y,
Munekage M, Uemura S, Maeda H, Kitagawa H, Kobayashi M and Hanazaki
K: Frequency and prognostic impact of cachexia during drug
treatment for unresectable advanced gastric cancer patients. Surg
Today. 52:1560–1567. 2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Morimoto K, Uchino J, Yokoi T, Kijima T,
Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, et al:
Impact of cancer cachexia on the therapeutic outcome of combined
chemoimmunotherapy in patients with non-small cell lung cancer: A
retrospective study. OncoImmunology. 10(1950411)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Nielsen C, Ohm-Laursen L, Barington T,
Husby S and Lillevang ST: Alternative splice variants of the human
PD-1 gene. Cell Immunol. 235:109–116. 2005.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Finkelmeier F, Canli Ö, Tal A, Pleli T,
Trojan J, Schmidt M, Kronenberger B, Zeuzem S, Piiper A, Greten FR
and Waidmann O: High levels of the soluble programmed death-ligand
(sPD-L1) identify hepatocellular carcinoma patients with a poor
prognosis. Eur J Cancer. 59:152–159. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chang B, Huang T, Wei H, Shen L, Zhu D, He
W, Chen Q, Zhang H, Li Y, Huang R, et al: The correlation and
prognostic value of serum levels of soluble programmed death
protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in
patients with hepatocellular carcinoma. Cancer Immunol Immunother.
68:353–363. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Okuma Y, Hosomi Y, Nakahara Y, Watanabe K,
Sagawa Y and Homma S: High plasma levels of soluble programmed cell
death ligand 1 are prognostic for reduced survival in advanced lung
cancer. Lung Cancer. 104:1–6. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Shigemori T, Toiyama Y, Okugawa Y,
Yamamoto A, Yin C, Narumi A, Ichikawa T, Ide S, Shimura T, Fujikawa
H, et al: Soluble PD-L1 expression in circulation as a predictive
marker for recurrence and prognosis in gastric cancer: Direct
comparison of the clinical burden between tissue and serum PD-L1
expression. Ann Surg Oncol. 26:876–883. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ito M, Oshima Y, Yajima S, Suzuki T,
Nanami T, Shiratori F, Funahashi K, Nemoto T and Shimada H: Is high
serum programmed death ligand 1 level a risk factor for poor
survival in patients with gastric cancer? Ann Gastroenterol Surg.
2:313–318. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Takahashi N, Iwasa S, Sasaki Y, Shoji H,
Honma Y, Takashima A, Okita NT, Kato K, Hamaguchi T and Yamada Y:
Serum levels of soluble programmed cell death ligand 1 as a
prognostic factor on the first-line treatment of metastatic or
recurrent gastric cancer. J Cancer Res Clin Oncol. 142:1727–1738.
2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Park W, Bang JH, Nam AR, Jin MH, Seo H,
Kim JM, Oh KS, Kim TY and Oh DY: Prognostic value of serum soluble
programmed death-ligand 1 and dynamics during chemotherapy in
advanced gastric cancer patients. Cancer Res Treat. 53:199–206.
2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Frigola X, Inman BA, Lohse CM, Krco CJ,
Cheville JC, Thompson RH, Leibovich B, Blute ML, Dong H and Kwon
ED: Identification of a soluble form of B7-H1 that retains
immunosuppressive activity and is associated with aggressive renal
cell carcinoma. Clin Cancer Res. 17:1915–1923. 2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tanaka H, Yoshii M, Imai T, Tamura T,
Toyokawa T, Muguruma K, Hirakawa K and Ohira M: Clinical
significance of coexisting histological diffuse type in stage
II/III gastric cancer. Mol Clin Oncol. 15(234)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Shiraishi T, Toyozumi T, Sakata H,
Murakami K, Kano M, Matsumoto Y, Yokoyama M, Okada K, Kamata T,
Ryuzaki T, et al: Soluble PD-L1 concentration is proportional to
the expression of PD-L1 in tissue and is associated with a poor
prognosis in esophageal squamous cell carcinoma. Oncology.
100:39–47. 2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Park JC, Lee YC, Kim JH, Kim YJ, Lee SK,
Hyung WJ, Noh SH and Kim CB: Clinicopathological aspects and
prognostic value with respect to age: An analysis of 3,362
consecutive gastric cancer patients. J Surg Oncol. 99:395–401.
2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Song P, Wu L, Jiang B, Liu Z, Cao K and
Guan W: Age-specific effects on the prognosis after surgery for
gastric cancer: A SEER population-based analysis. Oncotarget.
7:48614–48624. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Alshehri A, Alanezi H and Kim BS:
Prognosis factors of advanced gastric cancer according to sex and
age. World J Clin Cases. 8:1608–1619. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Imai Y, Chiba T, Kondo T, Kanzaki H,
Kanayama K, Ao J, Kojima R, Kusakabe Y, Nakamura M, Saito T, et al:
Interferon-γ induced PD-L1 expression and soluble PD-L1 production
in gastric cancer. Oncol Lett. 20:2161–2168. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Freeman GJ, Long AJ, Iwai Y, Bourque K,
Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne
MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a
novel B7 family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Iwai Y, Ishida M, Tanaka Y, Okazaki T,
Honjo T and Minato N: Involvement of PD-L1 on tumor cells in the
escape from host immune system and tumor immunotherapy by PD-L1
blockade. Proc Natl Acad Sci USA. 99:12293–12297. 2002.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Iwai Y, Terawaki S and Honjo T: PD-1
blockade inhibits hematogenous spread of poorly immunogenic tumor
cells by enhanced recruitment of effector T cells. Int Immunol.
17:133–144. 2005.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Akutsu Y, Murakami K, Kano M, Toyozumi T,
Matsumoto Y, Takahashi M, Otsuka R, Sekino N, Yokoyama M, Shiraishi
T and Matsubara H: The concentration of programmed cell
death-ligand 1 in the peripheral blood is a useful biomarker for
esophageal squamous cell carcinoma. Esophagus. 15:103–108.
2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhu Y, Zhu F, Ba H, Chen J and Bian X:
Helicobacter pylori infection and PD-L1 expression in gastric
cancer: A meta-analysis. Eur J Clin Invest.
53(e13880)2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Oh SY, Kim S, Keam B, Kim TM, Kim DW and
Heo DS: Soluble PD-L1 is a predictive and prognostic biomarker in
advanced cancer patients who receive immune checkpoint blockade
treatment. Sci Rep. 11(19712)2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chen G, Huang AC, Zhang W, Zhang G, Wu M,
Xu W, Yu Z, Yang J, Wang B, Sun H, et al: Exosomal PD-L1
contributes to immunosuppression and is associated with anti-PD-1
response. Nature. 560:382–386. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wei H, Wu F, Mao Y, Zhang Y, Leng G, Wang
J, Zhang W and Wang T: Measurement of soluble PD-1 and soluble
PD-L1 as well as PD-L1 and PD-1 from perioperative patients with
gastric carcinoma. Jpn J Clin Oncol. 52:331–345. 2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Naito T, Uchino J, Kojima T, Matano Y,
Minato K, Tanaka K, Mizukami T, Atagi S, Higashiguchi T, Muro K, et
al: A multicenter, open-label, single-arm study of anamorelin
(ONO-7643) in patients with cancer cachexia and low body mass
index. Cancer. 128:2025–2035. 2022.PubMed/NCBI View Article : Google Scholar
|
